Bone tissue metabolism in patients with rheumatoid arthritis treated with glucocorticosteroids;Metabolizm tkanki kostnej u chorych na reumatoidalne zapalenie stawów leczonych glikokortykosteroidami

Polskie Archiwum Medycyny Wewnetrznej

Volumn 104, Issue 2, 2000, Pages 455-465

  Korczowska, Izabela ^a   Ła̧cki, Jan K ^a   Leszczynski P ^a   Mackiewicz, Stefan H ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biochemical markers of osteoporosis; Glucocorticosteroids; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; OSTEOCALCIN; PREDNISONE; PROCOLLAGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOREARM; HUMAN; MALE; OSSIFICATION; OSTEOPOROSIS; RHEUMATOID ARTHRITIS;

EID: 0034470348     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Adachi D.J., Olszynski W., Hanley D.A. i wsp.: Management of corticosteroid-induced osteoporosis. Sem. Arthr. Rheum., 2000, 4, 228.
2. Anon G.: Consensus development conference: diagnosis, prophilaxis, and treatment of osteoporosis. Am. J. Med., 1993, 94, 646.
3. Als O.S., Christiansen C., Hellesen C.: Prevalance of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. Clin. Rheumatol., 1984, 3, 201.
4. Bocquet J., Daireanx M., Langris M. i wsp.: Effect of a interleukin-1 like factor (mononuclear cell factor) on proteoglycan synthesis in cultured human articular chondrocytes. Biochem. Biophys. Res. Commun., 1986, 134, 539.
5. Butler R.C., Davie M.W., Worsfold M., Sharp C.A.: Bone mineral content in patients with rheumatoid arthritis: relationship to low dose steroid therapy. Br. J. Rheumatol., 1991, 30, 86.
6. Charles P., Poser J.W., Mosekilde L, Jensen F.T.: Estimation of bone turnover evaluated by 47 calcium kinetics: efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excertion. J. Clin. Invest., 1985, 76, 2254.
7. Chin J.E., Lin Y.: Effects of recombinant human interleukin 1β on rabbit articular chondrocytes. Stimulation of prostanoid release and inhibition of cell growth. Arthritis. Rheum., 1988, 31, 1290.
8. Cartel B., Flipo R.M., Pigny P. i wsp.: How useful are bone turnover markers in rheumatoid arthritis? Rev-Rhum, 1997, 64, 153.
9. Eriksen E.F.: Normal and pathological remodelling of human trabecular bone: three dimensional reconstruction of the remodelling sequence in normal and in metabolic bone disease. Endocrine Rev., 1986, 7, 379.
10. Fujita T., Matsui T., Nakao Y., Shiozawa S., Imai Y: Cytokines and osteoporosis. Ann. NY Acad. Sci., 1990, 587, 371.
11. Gertzbein S.D., Lance E.M.: The stimulation of lymphocytes by chondrocytes in mixed cultures. Clin. Exp. Immunol., 1976, 24, 102.
12. Goldring M.B., Birkhead J.R., Sandell L.J., Kimura T., Krane S.M.: Interleukin I suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J. Clin. Invest., 1988, 82, 2026.
13. Goldring M.B., Birkhead J.R., Suen L.F. i wsp.: Interleukin-1 β-modulated gene expression in immortalized human chondrocytes. J. Clin. Invest., 1994, 94, 2307.
14. Gough A., Sambrook P., Devlin J. i wsp.: Osteoclastic activation is the principial mechanism leading to secondary osteoporosis in rheumatoid arthritis. J. Rheumatol., 1998, 25, 1282.
15. Hakala M., Aman S., Luukkainen R. i wsp.: Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann. Rheum. Dis., 1995, 54, 886.
16. Hall GM, Spector T.D., Griffin A.J., Jawad A.S., Hall M.L., Doyle D. K: The effect of rheumatoid arthritis and steroides therapy on bone density in postmenopausal women. Arthritis Rheum., 1993, 36, 1510.
17. Ishimi Y., Miyaura C., Jin C.H. i wsp.: IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol., 1990, 145, 3297.
18. Kolleritp G., Hansen M., Horslev-Peterson K.: Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Relation to disease activity and effects of methylprednisolone. Br. J. Rheumatol., 1994, 33, 816.
19. Korczowska I., Ła̧cki J.K.: Zastosowanie markerów biochemicznych w diagnostyce osteoporozy. Post. Nauk. Med., 1998, 11, 68.
20. Kroger H., Penttila LM., Alhava E.M.: Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand. J. Rheumatol., 1993, 22, 172.
21. Kroger H., Risteli J., Risteli L, Penttila L, Alhava E.: Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann. Rheum. Dis., 1993, 52, 338.
22. Loan R.F., Jansen T.L., van Kiel P.L.: Glucocorticosteroides in the management of rheumatoid arthritis. Rheumatology, 1999, 38, 6.
23. Lqcki J.K.: Management of the patients with severe refractory rheumatoid arthritis: are the never treatment options worth considering. BioDrugs, 2000, 13, 425.
24. Ła̧cki J.K., Klama K., Mackiewicz S.H., Mackiewicz U., Muller W.: Circulating interleukin-10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts. Preliminary report. Inflamm. Res., 1995, 44, 24.
25. Ła̧cki J.K., Sobieska M., Leszczynski P., Wiktorowicz K.: Microheterogenity of alpha 1-acid glycoprotein in rheumatoid arthritis patients treated with methotrexate. Ann. Rheum. Dis., 1994, 53, 480.
26. Malejczyk J.: Regulacja odtworzenia i niszczenia macierzy chrza̧stki stawowej. Terapia, 1997, 10, 46.
27. Michel B.A., Block D.A., Wolfe F., Fries J.F.: Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J. Rheumatol., 1993, 20, 1666.
28. Musial J., Tłustochowicz W.: Osteoporoza w reumatoidalnym zapaleniu stawów. Terapia, 1997, 10, 51.
29. Oelzner P., Franke S., Muller A., Hein G., Stein G.: Relationship between soluble markers of immune activation and bone turnover in postmenopausal woman with rheumatoid arthritis. Rheumatology Oxford, 1999, 38, 841.
30. Olbright T., Benker G.: Glucocorticosteroid induced osteoporosis: pathogenesis, prevention and treatment with special regard to the rheumatic diseases. J. Int. Med., 1993, 234, 237.
31. Parfit A.M.: The physiological and clinical significance of bone histomorphometric data. W: Recker R. (red): Bone Histomorphometry, Technics and Interpretation. CRC Press, Boca Raton, 1983, 143.
32. Pincus T.: Rheumatoid arthritis: a medical emergency? Scand. J. Rheumatol., 1994, 23, 21.
33. Ralston S.H., Russell R.G., Gowen M.: Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res., 1990, 5, 983.
34. Rico H., Herandez E.R., Gomez-Castresana E, Yague M., Cabranes J.A., Valor R.: Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histmorphometric study. Clin. Rheumatol., 1990, 9, 63.
35. Sajewicz I., Badurski J.E.: Wolne rodniki tlenowe i ich rola w patologii kostno-stawowej. Post. Osteoartr., 1992, 4, 23.
36. Suda T., Udagawa N., Nakamura I., Miyaura C., Takahashi N.: Modulation of osteoclast differentiation by local factors. Bone 1995, 17, 87S-91S.
37. Warenik-Szymankiewicz A.: Leczenie hormonalne osteoporozy w okresie postmenopauzalnym. Terapia, 1999, 10, 4.
38. Watts N.B.: Clinical utility of biochemical markers of bone remodeling. Clin. Chem., 1999, 45, 1359.